Sana Biotechnology Announces Elevated Focus on

Raising concentrate on ex vivo cell treatment platform centered on considerable preclinical and early translational medical knowledge suggesting capacity of hypoimmune (HIP)-modified cells to evade immune detection

Human evidence of notion knowledge in many scientific options – like oncology, autoimmune health conditions, and style 1 diabetes – anticipated in 2023 and 2024

IND submitted to investigate SC291 in various B-mobile-mediated autoimmune illnesses with preliminary proof of principle information expected in 2024

Enrollment proceeds in SC291 Section 1 ARDENT demo in patients with refractory B-mobile malignancies with data expected in 2023 and 2024

CTA submitted for investigator sponsored trial discovering HIP-modified primary islet cells in patients with type 1 diabetic issues on observe for initial HIP evidence of strategy facts in 2023 and 2024

IND submission for SC262 in patients with B-mobile malignancies who have failed a CD19 therapy on observe for this quarter with original proof of notion data predicted in 2024

Reducing close to-term expenditure on fusogen in vivo shipping platform scientific and preclinical packages, like delaying SG299 IND (in vivo CD19 Car or truck T)

2024 operating dollars melt away expected underneath $200 million adhering to 29% headcount reduction and lowered bills similar to the fusogen platform

SEATTLE, Oct. 10, 2023 (World NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a firm concentrated on altering the probable for sufferers by way of engineered cells, today announced a portfolio update, including the two improved focus on its ex vivo mobile therapy solution candidates and an IND submission for SC291 in autoimmune disorders. Sana is positioned to create scientific proof of thought from a number of plans in 2023 and 2024, with a purpose of better being familiar with its allogeneic HIP Car T packages in blood cancers, allogeneic HIP Car or truck T application in autoimmune disorders, and HIP pancreatic islet cells in variety 1 diabetic issues. The firm will lessen in close proximity to-phrase commit on its fusogen platform for in vivo gene shipping, which postpones the prepared SG299 IND and decreases its predicted ahead working burn up.

“We have greater self esteem in the probable of our HIP platform, and around-phrase, we are rising concentration on 3 therapeutic places that utilize this platform and have the potential to handle big unmet requires with healing intent – allogeneic Car T cells in oncology, allogeneic Motor vehicle T cells in autoimmune conditions, and pancreatic islet cell transplantation in sort 1 diabetes. We prepare to current clinical facts in these regions at many moments across 2023 and 2024,” said Steve Harr, President and CEO of Sana. “The SC291 IND submission for the cure of autoimmune health conditions positions us to go into the quickly rising opportunity of employing Car or truck T cells in these large and underserved populations, leveraging the investments we have created to day in the HIP system, T cell therapeutics, and scaled producing that can produce hundreds of client doses per operate. We will need to guarantee that we have a financeable charge construction with these emerging options factored in, and this strategic re-positioning enables us to supply significant scientific data throughout several drug candidates with the existing balance sheet. These improvements sadly indicate that lots of proficient and valued colleagues will depart the firm, and we thank them for their contributions and determination to our mission.”

Pick out Application Review

SC291 Oncology (HIP-modified CD19-directed allogeneic Automobile T): Enrollment continues in Sana’s ARDENT Stage 1 review for the treatment method of B-mobile lymphomas and leukemias with medical data predicted in 2023 and 2024.

SC291 Autoimmune (HIP-modified CD19-directed allogeneic Motor vehicle T): Sana submitted an IND for the remedy of many autoimmune ailments, with preliminary medical info predicted throughout a number of indications in 2024.

SC262 (HIP-modified CD22-directed allogeneic Automobile T): Sana expects to submit an IND in 4Q 2023 for the cure of B-cell lymphomas and leukemias in patients who have failed CD19-directed Car T therapies, with preliminary medical info predicted in 2024.

HIP-modified key islet cells for the remedy of form 1 diabetic issues: A CTA has been submitted for an investigator sponsored trial discovering the probable of HIP modifications to allogeneic most important islet cells to empower immune evasion and conquer transplant rejection in type 1 diabetic issues evidence of notion data expected in 2023 and 2024.

SG299 (in vivo Motor vehicle T with CD8-specific fusogen supply of a CD19-directed Auto): Sana will go on its centered exploration on this modern platform but not submit an IND at this time as beforehand prepared.

2024 Running Melt away Steerage

Sana expects 2024 functioning funds melt away to be below $200 million, allowing for the latest money placement to extend additional into 2025. The strategic re-positioning will lessen headcount by 29% whilst allowing for the enterprise to make investments in scientific capabilities throughout many indications in oncology, autoimmune health conditions, form 1 diabetic issues, and central anxious technique problems. Sana will leverage its present allogeneic production knowledge and continue advancement of its GMP production facility in Bothell, Washington.

About Sana Biotechnology
Sana Biotechnology, Inc. is focused on developing and providing engineered cells as medications for patients. We share a vision of controlling genes, replacing missing or ruined cells, and building our therapies broadly offered to individuals. We are a passionate team of people today doing the job collectively to build an enduring firm that adjustments how the entire world treats condition. Sana has operations in Seattle, Cambridge, South San Francisco, and Rochester. For more information and facts about Sana Biotechnology, please check out https://sana.com/.

Cautionary Note With regards to Forward-On the lookout Statements
This push release includes ahead-seeking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) in the that means of the federal securities legislation, which includes these similar to the Company’s eyesight, development, and enterprise plans expectations for its development courses, item candidates and know-how platforms, including its pre-medical, clinical and regulatory development options and timing anticipations, which includes with regard to the expected timing of IND submissions for the Company’s products candidates the Company’s expectations concerning the timing, compound, and effects of the facts from its clinical trials as perfectly as the investigator sponsored trial exploring HIP-modified largely islet cells in individuals with style 1 diabetes the possible skill of HIP-modified cells to evade immune detection and triumph over allogeneic rejection the Company’s envisioned 2024 functioning cash burn the opportunity impression of the Company’s reduction in its near-term shell out on the fusogen program, including on the timing of an IND submission for the SG299 plan and the Company’s ahead running melt away the Company’s expectations with respect to the likely therapeutic benefits and affect of its development systems and platforms, which includes in various indications the potential of SC291 to address autoimmune health conditions the opportunity impact of the portfolio update on the Company’s clinical and producing abilities and the Company’s long term designs with regard to its SG299 method. All statements other than statements of historic points contained in this push launch, which include, between other folks, statements about the Company’s tactic, anticipations, cash runway and upcoming financial problem, long run operations, and prospects, are ahead-on the lookout statements. In some cases, you can discover ahead-seeking statements by terminology this kind of as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other equivalent expressions that are predictions of or indicate upcoming functions and upcoming developments, or the destructive of these conditions or other similar terminology. The Company has primarily based these ahead-wanting statements mainly on its present-day anticipations, estimates, forecasts and projections about long term activities and monetary tendencies that it thinks may perhaps have an effect on its monetary condition, final results of functions, business method and fiscal requires. In gentle of the significant uncertainties in these ahead-hunting statements, you really should not count upon forward-searching statements as predictions of long term occasions. These statements are issue to dangers and uncertainties that could lead to the actual outcomes to fluctuate materially, like, amongst other people, the challenges inherent in drug growth this sort of as those people affiliated with the initiation, price, timing, progress and results of the Company’s present and potential exploration and advancement packages, preclinical and scientific trials, as perfectly as financial, current market and social disruptions. For a specific discussion of the risk variables that could influence the Company’s real final results, remember to refer to the possibility aspects recognized in the Company’s SEC stories, which include but not minimal to its Quarterly Report on Form 10-Q dated August 3, 2023. Apart from as needed by legislation, the Enterprise undertakes no obligation to update publicly any ahead-searching statements for any cause.

Trader Relations & Media:
Nicole Keith
[email protected]
[email protected]